Alberto Bresciani
About Alberto Bresciani
Alberto Bresciani serves as the Director of Project Biology at Exscientia, bringing extensive experience from previous roles at IRBM and Merck. He has a background in industrial biotechnology and specializes in protein biomarkers and assay development within GLP/GCP environments.
Current Role at Exscientia
Alberto Bresciani serves as the Director of Project Biology at Exscientia, a position he has held since 2022. His work is based in Oxford, United Kingdom. In this role, he focuses on advancing project biology initiatives, contributing to the company's efforts in drug discovery and development.
Previous Experience at IRBM
Bresciani has extensive experience at IRBM, where he held various leadership roles. He was the Director of Infectious Diseases from 2021 to 2022, Director of High Throughput Biology and Screening from 2019 to 2020, and Director of GLP/GCP Testing Facility during the same period. Additionally, he served as Director of Screening Technologies from 2015 to 2019 and Lab Head of Screening Technologies from 2010 to 2015. His tenure at IRBM spanned over a decade, emphasizing his expertise in the field.
Professional Involvement and Editorial Roles
Bresciani is an active member of the scientific community, serving on the Editorial Board of SLAS (Society for Laboratory Automation and Screening) since 2018. He was also a general committee member of ELRIG from 2008 to 2012. His involvement in these organizations highlights his commitment to advancing laboratory automation and screening methodologies.
Educational Background in Biotechnology
Alberto Bresciani studied at Università degli Studi di Milano-Bicocca, where he earned a degree in Industrial Biotechnology, achieving an MD from 2001 to 2005. This educational foundation has equipped him with the necessary skills and knowledge to excel in the pharmaceuticals industry.
Expertise in Drug Discovery and Development
Bresciani possesses strong skills in complex biology and assay development, with a demonstrated history of working in the pharmaceuticals industry. His expertise includes protein biomarkers within GLP/GCP environments, underscoring his contributions to research and development and drug discovery processes.